ZKSCAN3 and urinary bladder cancer: In vivo experiments further confirmed that ZKSCAN3-shRNA-treated bladder cancer cells had significantly diminished tumorigenicity in a xenograft mouse model, as evidenced by a reduction in tumor size and malignancy [54,87].